References
- Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
- Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
- Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-9
- Sellin L, Stegbauer J, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005;23:2083-92
- Pickering TG. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008;2:119-24
- Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46:156-61
- Fabia MJ, Abdilla N, Oltra R, et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25:1327-36
- Coltamai L, Maillard M, Simon A, et al. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens 2010;28:520-6
- Hasler C, Nussberger J, Maillard M, et al. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005;78:501-7
- Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma. Renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007;20:907-16
- Rump LC, Girerd X, Sellin L, et al. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens 2011;25:565-74
- Rump LC, Potthoff SA, Ammentorp B, et al. Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40/25 mg provides greater 24-hour ambulatory blood pressure-lowering versus OM/HCTZ 20/25 mg in patients with moderate-to-severe hypertension who are inadequately controlled by OM 40 mg monotherapy. J Hypertens 2010;28(e-Suppl A):5. 207
- Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006;26:185-93
- Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005;5:41-50
- Gosse P, Lasserre R, Minifie C, et al. Blood pressure surge on rising. J Hypertens 2004;22:1113-8
- Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008;51:55-61
- Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310